161 related articles for article (PubMed ID: 9352816)
1. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
[TBL] [Abstract][Full Text] [Related]
2. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.
Møller ML; Braendstrup O
J Neurooncol; 1997 Sep; 34(3):241-6. PubMed ID: 9258816
[TBL] [Abstract][Full Text] [Related]
3. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
4. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
Cobb MA; Husain M; Andersen BJ; al-Mefty O
J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
[TBL] [Abstract][Full Text] [Related]
5. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
6. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
7. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.
Nakabayashi H; Sakaguchi M; Katsuyama J; Hakuba A
J Neurooncol; 1995; 24(3):209-17. PubMed ID: 7595751
[TBL] [Abstract][Full Text] [Related]
8. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
9. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
14. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
15. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
16. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
17. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
18. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
19. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
20. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]